title: Quantitative Proteomics Identifies Activation of Hallmark Pathways of Cancer in Patient Melanoma.
abstract: Molecular pathways regulating melanoma initiation and progression are potential targets of therapeutic development for this aggressive cancer. Identification and molecular analysis of these pathways in patients has been primarily restricted to targeted studies on individual proteins. Here, we report the most comprehensive analysis of formalin-fixed paraffin-embedded human melanoma tissues using quantitative proteomics. From 61 patient samples, we identified 171 proteins varying in abundance among benign nevi, primary melanoma, and metastatic melanoma. Seventy-three percent of these proteins were validated by immunohistochemistry staining of malignant melanoma tissues from the Human Protein Atlas database. Our results reveal that molecular pathways involved with tumor cell proliferation, motility, and apoptosis are mis-regulated in melanoma. These data provide the most comprehensive proteome resource on patient melanoma and reveal insight into the molecular mechanisms driving melanoma progression.
authors: University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, Arkansas 72205, USA.
authors: Stephanie D
authors: SD
authors: Byrum
authors: Signe K
authors: SK
authors: Larson
authors: Nathan L
authors: NL
authors: Avaritt
authors: Linley E
authors: LE
authors: Moreland
authors: Samuel G
authors: SG
authors: Mackintosh
authors: Wang L
authors: WL
authors: Cheung
authors: Alan J
authors: AJ
authors: Tackett
keywords: FFPE tissue; Mass spectrometry; Melanoma; Proteomics; Quantitative
references: Nature. 1998 Oct 22;395(6704):808-13
references: 9796816
references: Clin Exp Metastasis. 2005;22(1):11-24
references: 16132574
references: J Invest Dermatol. 2006 Jan;126(1):161-6
references: 16417232
references: Oncogene. 2003 May 19;22(20):3138-51
references: 12789290
references: Nature. 1998 Jan 15;391(6664):298-301
references: 9440696
references: Kidney Int. 1992 Mar;41(3):665-70
references: 1573844
references: Clin Cancer Res. 2002 Dec;8(12):3728-33
references: 12473582
references: Cell. 2004 Nov 12;119(4):529-42
references: 15537542
references: J Biol Chem. 1993 Jan 5;268(1):502-9
references: 8416954
references: Pigment Cell Melanoma Res. 2010 Dec;23(6):849-52
references: 20849468
references: J Biol Chem. 2004 Feb 20;279(8):6235-43
references: 14638685
references: Mol Cell Biol. 1999 Aug;19(8):5308-15
references: 10409722
references: Lancet Oncol. 2002 Jan;3(1):35-43
references: 11905603
references: Histopathology. 2004 Oct;45(4):405-11
references: 15469480
references: Genome Res. 2007 Oct;17(10):1537-45
references: 17785539
references: Analyst. 2012 Jul 7;137(13):3146-53
references: 22582177
references: J Proteome Res. 2006 Sep;5(9):2339-47
references: 16944946
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Mayo Clin Proc. 2007 Mar;82(3):364-80
references: 17352373
references: PLoS One. 2009;4(2):e4430
references: 19221597
references: Clin Cancer Res. 2005 May 1;11(9):3175-83
references: 15867210
references: Biochem Biophys Res Commun. 2005 May 6;330(2):526-32
references: 15796914
references: Exp Cell Res. 2004 Jun 10;296(2):294-306
references: 15149859
references: J Pathol. 2008 Dec;216(4):387-93
references: 18853439
references: Biochim Biophys Acta. 2009 Jul;1790(7):589-99
references: 18929623
references: Clin Cancer Res. 2003 Dec 15;9(17):6483-8
references: 14695152
references: Pigment Cell Res. 2007 Jun;20(3):161-72
references: 17516924
references: Ann N Y Acad Sci. 1991;638:232-43
references: 1723854
references: Int J Cancer. 1993 Jan 21;53(2):278-84
references: 8425765
references: J Integr OMICS. 2011 Feb 1;1(1):61-65
references: 21709819
references: Biochim Biophys Acta. 1996 Jul 31;1275(3):161-203
references: 8695634
references: J Clin Bioinforma. 2011 Jul 07;1(1):17
references: 21884633
references: J Clin Oncol. 2005 Mar 1;23(7):1473-82
references: 15735123
references: Int J Cancer. 2001 Sep 1;93(5):617-22
references: 11477569
references: Cancer Immunol Immunother. 2012 May;61(5):599-614
references: 22366887
references: Int J Proteomics. 2011;2011:181890
references: 22084682
references: J Exp Med. 2006 Jul 10;203(7):1651-6
references: 16801397
references: J Cutan Pathol. 2011 Nov;38(11):933-6
references: 21883366
references: Nat Med. 2012 Jun 06;18(6):853-4
references: 22673991
references: Proteomics Clin Appl. 2007 Sep;1(9):1080-9
references: 21136759
references: J Biol Chem. 1996 Aug 2;271(31):18961-5
references: 8702560
references: Chin Med J (Engl). 2004 Feb;117(2):213-8
references: 14975205
references: Arch Dermatol. 1986 May;122(5):507-8
references: 3707165
references: Bioessays. 1992 Jan;14(1):49-56
references: 1546980
references: J Clin Oncol. 2001 Aug 15;19(16):3635-48
references: 11504745
references: Science. 2003 Jan 10;299(5604):223-6
references: 12522243
references: Nucleic Acids Res. 2000 Jan 1;28(1):27-30
references: 10592173
references: Dermatol Res Pract. 2012;2012:354191
references: 22013435
references: Cancer Res. 2009 Mar 15;69(6):2224-33
references: 19244113
references: Int J Cancer. 1998 Sep 25;78(1):41-5
references: 9724092
references: J Cell Biol. 2006 Jun 5;173(5):767-80
references: 16754960
references: RNA. 2004 Feb;10(2):200-9
references: 14730019
references: Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
references: 14685170
references: J Cell Sci. 2006 Jul 1;119(Pt 13):2715-26
references: 16757518
references: Annu Rev Plant Biol. 2010;61:491-516
references: 20192741
references: J Cell Sci. 2009 Oct 1;122(Pt 19):3492-501
references: 19723803
references: Genes Cells. 2003 Dec;8(12):1019-27
references: 14750956
references: Cancer Treat Rev. 2004 Apr;30(2):193-204
references: 15023437